RSS Feeds
Melphalan and Myeloma
Experience with a Low-Dose Continuous Regimen
- JAMES R. MCARTHUR, M.D.;
- JOHN W. ATHENS, M.D., F.A.C.P.;
- MAXWELL M. WINTROBE, M.D., Ph.D., F.A.C.P.; and
- GEORGE E. CARTWRIGHT, M.D., F.A.C.P.
Abstract
Sixty-seven patients with symptomatic multiple myeloma were studied. Thirty-nine were treated with melphalan. The initial dose of 4 mg by mouth daily was reduced if the white blood count fell below 2,000 to 2,500/mm3. There were significant objective and subjective improvement and increased survival in the melphalan-treated patients as compared with a retrospective control group of 28 patients. The results compare favorably with reported series in which high-dose intermittent regimens were used. Information is insufficient to compare toxicity and complications associated with the two regimens.
Article and Author Information
-
▸From the Department of Internal Medicine, University of Utah College of Medicine, Salt Lake City, Utah.
-
Supported in part by grants AM-5098 and AM-04489, U. S. Public Health Service, Washington, D. C.
-
Dr. McArthur was supported in this study as an Advanced Clinical Fellow, 1965-1968, American Cancer Society, New York.
-
▸Requests for reprints should be addressed to James R. McArthur, M.D., University of Minnesota Hospitals, Minneapolis, Minn. 55455
-
- Received December 9, 1969.
- Accepted December 18, 1969.
Related Clinical Content
